How do I tell if a peptide is overpriced?

The short answer

To know whether a peptide is overpriced, ignore the sticker price and compute price-per-milligram: vial price divided by total milligrams in the vial. That single number lets you compare any two listings fairly, see through vial-size tricks, and judge a price against the typical range for that compound and channel.

Evidence tier: This is Tier 4 — a consumer-math explainer, not a clinical claim. The method is simple arithmetic; the "typical ranges" move constantly and are illustrative.

The essentials:

• Price-per-mg = vial price ÷ total mg — the only fair comparison.
• Sticker price misleads because vial sizes differ.
• Compare within the same channel — gray-market to gray-market, not to brand.
• A figure far below the range is a red flag, not a win.

This is a practical companion to our peptide cost and pricing cornerstone. For the sourcing-safety context see the peptide safety and sourcing guide.

The one calculation that matters

Evidence tier: 4 — basic arithmetic.

Everything in peptide price comparison reduces to one operation: take the price of the vial and divide it by the number of milligrams it contains. A vial of BPC-157 listed at $45 containing 5 mg costs $9 per milligram. A vial listed at $70 containing 10 mg costs $7 per milligram. The second vial costs more up front but is cheaper per unit of actual product — and per unit is what you're really buying, because you dose in milligrams, not in vials.

This sounds trivial, and it is, but it's the step almost nobody does consistently, which is exactly why vendors can present prices in ways that obscure value. Once you make price-per-mg a reflex, the comparison becomes objective: you line up the per-mg figures and the cheapest real option is obvious, independent of how the listings are dressed up. The number also travels — you can compare a per-mg figure you computed last month to one today, or one vendor to another, on equal footing. It's the universal unit of peptide cost, and learning to compute it instantly is the single most useful price skill there is. Our cost cornerstone places it in the bigger picture.

Why vial size is used to hide the real price

Evidence tier: 4 — pricing-presentation tactics.

Vendors know buyers anchor on the sticker price, so vial size becomes a lever for making a price look better than it is. A small vial can carry a low sticker that feels cheap while being expensive per mg — a $30 vial of 3 mg is $10/mg, pricier than a $60 vial of 10 mg at $6/mg, even though $30 is the smaller number. Conversely, a large vial can carry a scary sticker that's actually excellent value per mg, deterring buyers who only look at the total. Neither presentation is necessarily dishonest, but both exploit the failure to compute per-mg.

There's a second wrinkle: the dose you'll actually use. A compound dosed at small microgram amounts will last far longer per mg than one dosed at several milligrams per administration, so two peptides at the same price-per-mg can have very different costs-per-course. The full picture is price-per-mg combined with how many mg a typical course consumes — which tells you cost per course, the figure that actually hits your wallet. For most comparisons within a single compound, price-per-mg is enough; when comparing across compounds with very different dosing, step up to cost-per-course. Our reconstitution and dosing guide helps translate mg into doses.

Worked examples

Evidence tier: 4 — illustrative arithmetic.

Consider three listings for the same gray-market peptide. Vendor A: $40 for a 5 mg vial → $8/mg. Vendor B: $90 for a 10 mg vial → $9/mg. Vendor C: $150 for a 20 mg vial → $7.50/mg. The sticker order (A cheapest, C most expensive) completely inverts the value order: C is the best per-mg value, A is middling, B is the worst despite sitting between them on sticker price. Without the per-mg calculation, a buyer drawn to A's low entry price overpays per unit versus C, and a buyer scared off C's high sticker misses the best deal.

Now add the course dimension. Suppose a typical course of this peptide uses 10 mg. Then Vendor A requires two 5 mg vials ($80), B one 10 mg vial ($90), C one 20 mg vial with half left over ($150, or effectively $75 of peptide used). On a strict cost-of-peptide-used basis, C still wins, but A is competitive and avoids paying for product you won't use soon (relevant given peptides degrade and storage matters). This is the kind of reasoning price-per-mg unlocks: it turns a confusing set of stickers into a clear ranking, and combined with course size, into an actual budget. The takeaway isn't a single "right" vendor — it's that you can now see the real numbers instead of guessing.

How do I know if the per-mg price is reasonable?

Evidence tier: 3–4 — range-and-channel judgment.

A per-mg figure is only meaningful against a reference range, and the reference is the typical price for that compound in that channel. Comparing a gray-market per-mg price to a brand pharmaceutical one is meaningless — they're different products. Within the gray market, prices for a given peptide cluster into a rough range, and the useful judgment is where a listing falls: near the middle is normal, somewhat above can be justified by testing and quality (see below), and far below is a warning sign rather than a triumph.

That last point is the one people get wrong. A price-per-mg dramatically under the typical range usually doesn't mean you found a uniquely efficient vendor — it means the product is likely underdosed (so the real per-mg, adjusted for actual content, is higher than it looks), untested, or counterfeit (FDA counterfeit semaglutide warning). Substandard and falsified medicines are a documented, large-scale problem (Ozawa 2018). So "reasonable" means within the sane channel range, not the lowest number you can find. Our pricing red-flags article details the warning signs, and our cost cornerstone explains why testing justifies a modest premium.

When paying more per mg is the smart move

Evidence tier: 4 — value-adjusted pricing.

Lowest per-mg isn't automatically best, because per-mg measures price, not value. The thing per-mg can't capture is what's actually in the vial and whether it's safe — and that's the whole risk of the gray market. A vendor charging modestly above the cheapest options, who publishes third-party certificates of analysis, tests for purity and identity, and handles sterility properly, is selling a meaningfully better product than the rock-bottom listing with no testing. Paying a few dollars more per mg for verified content is usually the best value decision in this market, because it directly buys down the central risk.

So the refined rule is: compute price-per-mg to compare on a level field, then adjust for verification. Reject the listings far below the range (red flags), then among the sane-priced options, prefer the one whose testing and practices you can actually confirm over the one that's marginally cheaper but unverifiable. That's how you avoid both overpaying for branding and underpaying into a counterfeit. Verification services like Finnrick and the habit of reading a certificate of analysis are what let you make that value adjustment with real information rather than hope.

What about bundles, bulk discounts, and sales?

Evidence tier: 4 — promotional-pricing judgment.

Vendors lean heavily on bundles, bulk discounts, and recurring sales, and price-per-mg is exactly the tool for evaluating them honestly. A "buy three, save 20%" deal is only good if the discounted per-mg figure beats what you'd pay buying singles elsewhere — and sometimes the bundle's baseline price is inflated so the "discount" merely lands at the normal rate. Run the per-mg math on the bundled price and compare it to the market; if it's genuinely lower for a product you'd use before it degrades, it's a real saving, and if not, it's marketing.

Bulk's specific trap is that buying a large quantity of an unverified product to save per-mg multiplies your exposure if that product turns out to be underdosed or contaminated — you've now committed money and risk to a bigger batch. The sound version is to verify a vendor with a small order first, and only scale up to bulk pricing once testing or experience has confirmed the product. That sequencing — verify small, then buy bulk — captures the per-mg savings without betting a large sum on an unconfirmed source. Sales work the same way: a discount on a tested, trusted vendor is a genuine win; a discount as the reason to try an unknown one inverts the priorities.

Limitations

This is an educational guide, not medical, legal, or financial advice.

• Typical price ranges change constantly — figures here are illustrative, not quotes.
• Price-per-mg measures price, not value — adjust for testing and verification.
• Compare within the same channel — gray-market to gray-market only.
• A figure far below the range is a red flag, often underdosing or counterfeit.
• Cost-per-course matters too when comparing compounds with very different doses.
• Gray-market sourcing carries real risk — verify via Finnrick.
• Marko Maal, MSc Pharmacy reviewed this article. Reviewer attribution does not constitute a doctor-patient relationship.

The bottom line

To judge whether a peptide is overpriced, compute price-per-milligram — vial price divided by total milligrams — and compare that, not the sticker, across listings in the same channel. Vial size is routinely used to make prices look better or worse than they are, and only per-mg cuts through it; worked examples show the sticker order can completely invert the value order. Judge the per-mg figure against the typical range for that compound and channel: middle is normal, a modest premium can buy real testing, and far below the range is a red flag for underdosing or counterfeits, not a bargain.

The discipline that makes you hard to overcharge — and hard to scam — is to make price-per-mg automatic and then adjust for verification. Reject the suspiciously cheap, ignore the scary-but-good-value stickers, and among sanely priced options pay the small premium for documented third-party testing. That sequence turns a confusing, manipulable set of prices into a clear, value-adjusted decision, and it keeps your money pointed at actual verified product rather than at whichever listing happened to be dressed up most appealingly. Per-mg first, verification second, lowest-number never on its own.

Related on this site

• Peptide cost and pricing cornerstone (2026)
• Too-good-to-be-true peptide pricing: red flags
• GLP-1 cost-saving strategies (done safely)
• How to read a peptide certificate of analysis
• Peptide reconstitution and dosing guide
• Peptide safety and sourcing guide (2026)
• Our evidence-tier framework
• Finnrick vendor testing

References

• U.S. Food and Drug Administration. FDA warns against use of counterfeit and compounded semaglutide. FDA.gov — counterfeit and underdosed product risk.
• Ozawa S, Evans DR, Bessias S, et al. 2018. Prevalence and estimated economic burden of substandard and falsified medicines. JAMA Netw Open. 1(4):e181662. PMID 30646106 — scale of substandard/falsified medicines.
• U.S. Food and Drug Administration. Compounding and the FDA: Questions and Answers. FDA.gov — channel definitions behind price differences.